TR199802160T2 - Ateroskleroz tedavisi i�in azetidinon t�revleri. - Google Patents
Ateroskleroz tedavisi i�in azetidinon t�revleri.Info
- Publication number
- TR199802160T2 TR199802160T2 TR1998/02160T TR9802160T TR199802160T2 TR 199802160 T2 TR199802160 T2 TR 199802160T2 TR 1998/02160 T TR1998/02160 T TR 1998/02160T TR 9802160 T TR9802160 T TR 9802160T TR 199802160 T2 TR199802160 T2 TR 199802160T2
- Authority
- TR
- Turkey
- Prior art keywords
- atherosclerosis
- treatment
- hydrogen
- pharmaceutically acceptable
- optionally substituted
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 abstract 1
- 108010024976 Asparaginase Proteins 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 235000019256 formaldehyde Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9608646.7A GB9608646D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GBGB9623756.5A GB9623756D0 (en) | 1996-11-15 | 1996-11-15 | Novel compounds |
| GBGB9625121.0A GB9625121D0 (en) | 1996-12-03 | 1996-12-03 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199802160T2 true TR199802160T2 (xx) | 1999-04-21 |
Family
ID=27268259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1998/02160T TR199802160T2 (xx) | 1996-04-26 | 1997-04-15 | Ateroskleroz tedavisi i�in azetidinon t�revleri. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0915843A1 (cs) |
| JP (1) | JP2000509049A (cs) |
| AR (1) | AR006833A1 (cs) |
| AU (1) | AU2698697A (cs) |
| BR (1) | BR9709196A (cs) |
| CA (1) | CA2252696A1 (cs) |
| CZ (1) | CZ341098A3 (cs) |
| HU (1) | HUP9901359A3 (cs) |
| ID (1) | ID16660A (cs) |
| IL (1) | IL126696A0 (cs) |
| MA (1) | MA26426A1 (cs) |
| NO (1) | NO984939L (cs) |
| NZ (1) | NZ332476A (cs) |
| PE (1) | PE64398A1 (cs) |
| PL (1) | PL329530A1 (cs) |
| TR (1) | TR199802160T2 (cs) |
| WO (1) | WO1997041098A1 (cs) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60121550T2 (de) | 2000-02-16 | 2007-06-21 | Smithkline Beecham Plc, Brentford | Pyrimidin-4-onderivat als LDL-PLA2 Inhibitor |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| ME00145B (me) | 2001-01-26 | 2010-10-10 | Merck Sharp & Dohme | Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije |
| UA75644C2 (en) | 2001-03-28 | 2006-05-15 | Schering Corp | Enantioselective synthesis of azetidinone intermediate compounds |
| DE60216275T2 (de) * | 2001-05-25 | 2007-06-21 | Schering Corp. | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| ATE406364T1 (de) | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| WO2004081003A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| US9029383B2 (en) | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| EA200971050A1 (ru) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |
| EA023796B1 (ru) | 2010-12-06 | 2016-07-29 | Глэксо Груп Лимитед | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA |
| JP2013545792A (ja) | 2010-12-17 | 2013-12-26 | グラクソ グループ リミテッド | 眼疾患の処置および防止方法 |
| EP2725024A4 (en) | 2011-06-27 | 2014-12-03 | Shanghai Inst Materia Medica | HETEROCYCLIC AZOL COMPOUND, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| KR20140059204A (ko) | 2011-07-27 | 2014-05-15 | 글락소 그룹 리미티드 | 비시클릭 피리미돈 화합물 |
| WO2013013503A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| WO2014114249A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
| CN105008368B (zh) | 2013-01-25 | 2017-02-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 基于2,3‑二氢咪唑并[1,2‑c]嘧啶‑5(1H)‑酮的脂蛋白相关磷脂酶A2(Lp‑PLA2)抑制剂 |
| WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CA3156783A1 (en) | 2019-11-09 | 2021-05-14 | Yun Jin | Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| WO1993000332A1 (en) * | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| WO1993002048A1 (en) * | 1991-07-23 | 1993-02-04 | Schering Corporation | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
| CA2108584C (en) * | 1992-10-27 | 1998-11-24 | James B. Doherty | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| WO1994013636A1 (en) * | 1992-12-17 | 1994-06-23 | Merck & Co., Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| EP0974663A1 (en) * | 1993-06-25 | 2000-01-26 | Smithkline Beecham Plc | Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy |
| DE69434609T2 (de) * | 1993-10-06 | 2006-09-21 | Icos Corp., Bothell | Acethylhydrolase des Plättchen aktivierenden Faktors |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| HUT77089A (hu) * | 1994-12-22 | 1998-03-02 | Smithkline Beecham Plc. | Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| AU5014496A (en) * | 1995-03-23 | 1996-10-08 | Japan Tobacco Inc. | Diphenylmethyl-azetidinone compounds and elastase inhibitor |
| BR9609445A (pt) * | 1995-07-01 | 1999-04-06 | Smithkline Beecham Plc | Derivados de azetidinona no tratamento de aterosclerose |
| WO1997021676A1 (en) * | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
-
1997
- 1997-04-15 NZ NZ332476A patent/NZ332476A/en unknown
- 1997-04-15 HU HU9901359A patent/HUP9901359A3/hu unknown
- 1997-04-15 CA CA002252696A patent/CA2252696A1/en not_active Abandoned
- 1997-04-15 EP EP97920699A patent/EP0915843A1/en not_active Withdrawn
- 1997-04-15 JP JP9538507A patent/JP2000509049A/ja active Pending
- 1997-04-15 PL PL97329530A patent/PL329530A1/xx unknown
- 1997-04-15 WO PCT/EP1997/001898 patent/WO1997041098A1/en not_active Ceased
- 1997-04-15 IL IL12669697A patent/IL126696A0/xx unknown
- 1997-04-15 AU AU26986/97A patent/AU2698697A/en not_active Abandoned
- 1997-04-15 CZ CZ983410A patent/CZ341098A3/cs unknown
- 1997-04-15 TR TR1998/02160T patent/TR199802160T2/xx unknown
- 1997-04-15 BR BR9709196A patent/BR9709196A/pt not_active Application Discontinuation
- 1997-04-24 AR ARP970101682A patent/AR006833A1/es unknown
- 1997-04-24 MA MA24565A patent/MA26426A1/fr unknown
- 1997-04-24 PE PE1997000311A patent/PE64398A1/es not_active Application Discontinuation
- 1997-04-25 ID IDP971394A patent/ID16660A/id unknown
-
1998
- 1998-10-23 NO NO984939A patent/NO984939L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9901359A3 (en) | 2000-03-28 |
| EP0915843A1 (en) | 1999-05-19 |
| AU2698697A (en) | 1997-11-19 |
| IL126696A0 (en) | 1999-08-17 |
| MA26426A1 (fr) | 2004-12-20 |
| PE64398A1 (es) | 1999-01-06 |
| JP2000509049A (ja) | 2000-07-18 |
| NO984939L (no) | 1998-12-23 |
| PL329530A1 (en) | 1999-03-29 |
| CZ341098A3 (cs) | 1999-03-17 |
| NO984939D0 (no) | 1998-10-23 |
| AR006833A1 (es) | 1999-09-29 |
| ID16660A (id) | 1997-10-30 |
| BR9709196A (pt) | 1999-05-25 |
| WO1997041098A1 (en) | 1997-11-06 |
| HUP9901359A2 (hu) | 1999-08-30 |
| CA2252696A1 (en) | 1997-11-06 |
| NZ332476A (en) | 2000-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199802160T2 (xx) | Ateroskleroz tedavisi i�in azetidinon t�revleri. | |
| DE69503647D1 (de) | Aminoheterocyclische derivate als antithrombotische oder antikoagulierende mittel | |
| ES2187660T3 (es) | Derivados de rapamicina. | |
| ES2134847T3 (es) | Derivados de taxol. | |
| NO972909L (no) | Substituerte azetidin-2-oner for behandling av atherosklerose | |
| DE69705480D1 (de) | Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung | |
| EA200000416A1 (ru) | Новые арилоксиалкилдиалкиламины | |
| YU89691A (sh) | Postupak za dobijanje stereoselektivnih derivata fenilizoserina | |
| ATE191473T1 (de) | 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung | |
| NZ311684A (en) | Azetidinone derivatives, preparation, and use for treating atherosclerosis | |
| TR199902897T2 (xx) | S�v� benz-izo-kuinolin t�revleri. | |
| TR199801039T2 (xx) | Yeni fenilamidin t�revlerinin elde edilmesine y�nelik usul. | |
| DE69719511D1 (de) | Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung | |
| DE69707672D1 (de) | Dibenzo-oxazepin- und dioxepin-derivate und ihre verwendung als antitumormittel | |
| DE69311123D1 (de) | Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe | |
| NO994104L (no) | 5-hydroksymetyl-2-aminotetraliner i form av kardiovaskulaere midler | |
| KR970706280A (ko) | 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists) | |
| ATE206431T1 (de) | Antifungal fusacandine | |
| MX9708422A (es) | Esteres de carbapenemas. | |
| TR199701286T1 (xx) | Karbapenemlerin esterleri. | |
| AU2001270562A1 (en) | Agent for colouring keratin-containing fibres | |
| MA20638A1 (fr) | Nouveaux derives de la pyrrolo(1,2-a)azepinone, leur preparation et les compositions qui les contiennent | |
| IT1272881B (it) | Composti arilalchilenici | |
| ECSP972092A (es) | Nuevos compuestos monociclicos de b lactama procedimientos para su preparacion |